Island Pharmaceuticals Ltd (ASX:ILA) CEO David Foster speaks with Proactive soon after receiving Investigational New Drug (IND) clearance and the lifting of a clinical hold for its lead ISLA-101 clinical program from the US Food and Drug Administration (FDA). ISLA-101 is being repurposed for the prevention and treatment of dengue fever and other mosquito borne diseases. The company is moving rapidly into clinical trials for dengue-infected patients.
Island Pharmaceuticals sees tremendous opportunity for mosquito-borne virus program
